Lowest-Rated StocksLowest-RatedNASDAQ:GMAB Genmab A/S (GMAB) Stock Forecast, Price & News $39.57 +0.24 (+0.61%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$39.01▼$39.5750-Day Range$37.12▼$42.9452-Week Range$26.19▼$47.50Volume258,086 shsAverage Volume347,047 shsMarket Capitalization$26.11 billionP/E Ratio35.65Dividend YieldN/APrice Target$39.15 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Genmab A/S MarketRank™ ForecastAnalyst RatingHold2.08 Rating ScoreUpside/Downside1,498.7% Upside$632.62 Price TargetShort InterestHealthy0.51% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth30.30%From $0.99 to $1.29 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.33 out of 5 starsMedical Sector178th out of 983 stocksPharmaceutical Preparations Industry77th out of 486 stocks 3.0 Analyst's Opinion Consensus RatingGenmab A/S has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 3 buy ratings, 7 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $632.62, Genmab A/S has a forecasted upside of 1,498.7% from its current price of $39.57.Amount of Analyst CoverageGenmab A/S has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.51% of the outstanding shares of Genmab A/S have been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Genmab A/S has recently decreased by 4.52%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GMAB. Previous Next 2.6 News and Social Media Coverage News SentimentGenmab A/S has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Genmab A/S this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsOnly 6.73% of the stock of Genmab A/S is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Genmab A/S are expected to grow by 30.30% in the coming year, from $0.99 to $1.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 35.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 35.65, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.17.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 1.95. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 6.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Genmab A/S (NASDAQ:GMAB) StockGenmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.Read More Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address GMAB Stock News HeadlinesJune 2, 2023 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Research Coverage Started at UBS GroupMay 29, 2023 | markets.businessinsider.comSVB Securities Sticks to Its Hold Rating for Genmab (GMAB)June 4, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...May 28, 2023 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Receives $752.95 Consensus PT from AnalystsMay 27, 2023 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) to Post FY2024 Earnings of $0.83 Per Share, HC Wainwright ForecastsMay 26, 2023 | americanbankingnews.comGenmab A/S to Post Q2 2024 Earnings of $0.25 Per Share, HC Wainwright Forecasts (NASDAQ:GMAB)May 26, 2023 | americanbankingnews.comGenmab A/S to Post FY2023 Earnings of $1.01 Per Share, William Blair Forecasts (NASDAQ:GMAB)May 25, 2023 | finance.yahoo.comGenmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) CongressJune 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 24, 2023 | americanbankingnews.comHC Wainwright Boosts Genmab A/S (NASDAQ:GMAB) Price Target to $51.00May 22, 2023 | finance.yahoo.comAbbVie (ABBV) Gets FDA Nod for Lymphoma Drug EpcoritamabMay 20, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Genmab A/S Lifted by HC Wainwright (NASDAQ:GMAB)May 19, 2023 | msn.comAbbVie, Genmab granted FDA nod for lymphoma therapyMay 19, 2023 | msn.comFDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult PatientsMay 19, 2023 | reuters.comUS FDA approves Genmab-AbbVie's blood cancer therapyMay 16, 2023 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) PT Raised to $47.00 at HC WainwrightMay 16, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Genmab A/S Issued By SVB Leerink (NASDAQ:GMAB)May 16, 2023 | americanbankingnews.comGenmab A/S Forecasted to Earn Q2 2023 Earnings of $0.28 Per Share (NASDAQ:GMAB)May 14, 2023 | americanbankingnews.comQ3 2023 EPS Estimates for Genmab A/S (NASDAQ:GMAB) Increased by AnalystMay 13, 2023 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Shares Gap Up to $40.35May 12, 2023 | msn.com8 Best Biotech Stocks to Buy in 2023May 12, 2023 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Receives New Coverage from Analysts at Morgan StanleyMay 11, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (GMAB) and Innate Pharma (IPHA)May 10, 2023 | msn.comGenmab A/S GAAP EPS of DKK3.43 beats by DKK3.27, revenue of DKK2.85BMay 8, 2023 | msn.comHow To Attend Genmab Q1 2023 Earnings Conference CallMay 5, 2023 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Receives Consensus Recommendation of "Hold" from AnalystsApril 27, 2023 | msn.comPrice Over Earnings Overview: GenmabSee More Headlines GMAB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMAB Company Calendar Last Earnings11/10/2021Today6/03/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GMAB CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees1,660Year Founded1999Price Target and Rating Average Stock Price Forecast$632.62 High Stock Price Forecast$3,600.00 Low Stock Price Forecast$31.00 Forecasted Upside/Downside-1.1%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$1.11 Trailing P/E Ratio35.65 Forward P/E Ratio39.97 P/E Growth1.95Net Income$781.91 million Net Margins34.34% Pretax Margin44.26% Return on Equity19.67% Return on Assets17.52% Debt Debt-to-Equity RatioN/A Current Ratio14.44 Quick Ratio14.44 Sales & Book Value Annual Sales$2.07 billion Price / Sales12.63 Cash Flow$1.27 per share Price / Cash Flow31.13 Book Value$5.94 per share Price / Book6.66Miscellaneous Outstanding Shares659,860,000Free Float649,697,000Market Cap$26.11 billion OptionableNot Optionable Beta0.96 Social Links Key ExecutivesJan G. J. van de WinkelPresident & Chief Executive OfficerAnthony ManciniChief Operating Officer & Executive Vice PresidentAnthony PaganoChief Financial Officer & Executive Vice PresidentTahamtan AhmadiChief Medical Officer & Executive Vice PresidentMartine J. van VugtChief Strategy Officer & Executive Vice PresidentKey CompetitorsAlnylam PharmaceuticalsNASDAQ:ALNYHorizon Therapeutics PublicNASDAQ:HZNPBeiGeneNASDAQ:BGNEBioMarin PharmaceuticalNASDAQ:BMRNSarepta TherapeuticsNASDAQ:SRPTView All CompetitorsInstitutional OwnershipJPMorgan Chase & Co.Sold 32,546 shares on 5/18/2023Ownership: 0.025%International Biotechnology Trust PLCBought 88,000 shares on 5/18/2023Ownership: 0.013%Rockefeller Capital Management L.P.Bought 310 shares on 5/17/2023Ownership: 0.003%Geode Capital Management LLCSold 535 shares on 5/16/2023Ownership: 0.006%Snowden Capital Advisors LLCBought 633 shares on 5/16/2023Ownership: 0.001%View All Institutional Transactions GMAB Stock - Frequently Asked Questions Should I buy or sell Genmab A/S stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 2 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares. View GMAB analyst ratings or view top-rated stocks. What is Genmab A/S's stock price forecast for 2023? 12 Wall Street analysts have issued 12 month price targets for Genmab A/S's shares. Their GMAB share price forecasts range from $31.00 to $3,600.00. On average, they expect the company's stock price to reach $632.62 in the next twelve months. This suggests a possible upside of 1,498.7% from the stock's current price. View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts. How have GMAB shares performed in 2023? Genmab A/S's stock was trading at $42.38 on January 1st, 2023. Since then, GMAB stock has decreased by 6.6% and is now trading at $39.57. View the best growth stocks for 2023 here. When is Genmab A/S's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our GMAB earnings forecast. How were Genmab A/S's earnings last quarter? Genmab A/S (NASDAQ:GMAB) released its quarterly earnings results on Wednesday, November, 10th. The company reported $0.21 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.10. The company earned $366.25 million during the quarter, compared to analysts' expectations of $341.46 million. Genmab A/S had a net margin of 34.34% and a trailing twelve-month return on equity of 19.67%. During the same quarter last year, the business posted $0.13 earnings per share. What ETFs hold Genmab A/S's stock? ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Goldman Sachs Future Health Care Equity ETF (GDOC), WisdomTree BioRevolution Fund (WDNA), BlackRock Future Health ETF (BMED), Pacer Trendpilot International ETF (PTIN) and Invesco Nasdaq Biotechnology ETF (IBBQ). What guidance has Genmab A/S issued on next quarter's earnings? Genmab A/S updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.94 billion-$2.13 billion, compared to the consensus revenue estimate of $2.31 billion. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO). When did Genmab A/S IPO? (GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. What is Genmab A/S's stock symbol? Genmab A/S trades on the NASDAQ under the ticker symbol "GMAB." Who are Genmab A/S's major shareholders? Genmab A/S's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.80%), Macquarie Group Ltd. (0.53%), Wellington Management Group LLP (0.37%), 1832 Asset Management L.P. (0.34%), First Trust Advisors LP (0.19%) and Envestnet Asset Management Inc. (0.17%). How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Genmab A/S's stock price today? One share of GMAB stock can currently be purchased for approximately $39.57. How much money does Genmab A/S make? Genmab A/S (NASDAQ:GMAB) has a market capitalization of $26.11 billion and generates $2.07 billion in revenue each year. The company earns $781.91 million in net income (profit) each year or $1.11 on an earnings per share basis. How many employees does Genmab A/S have? The company employs 1,660 workers across the globe. How can I contact Genmab A/S? Genmab A/S's mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The official website for the company is www.genmab.com. The company can be reached via phone at (457) 020-2728 or via email at acn@genmab.com. This page (NASDAQ:GMAB) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.